Organization Overview
Founded in 2015 by Calgary-based Brad Sorenson, Providence Therapeutics Holdings Inc is a clinical-stage biotechnology company focused on drug development and platform development.
The Providence mRNA Medicines platform is comprised of three integrated platforms: 1) mRNA Medicines Platform, 2) INTENT™ Lipid Nanoparticle Platform (LNP), and 3) Manufacturing Platform. Providence’s mRNA and INTENT™ LNP platform offer an end-to-end solution for designing codon-optimized ultrapure mRNA that can be formulated in application-optimized LNP. The Providence proprietary INTENT™ LNP platform, consists of rationally designed lipids that have been tested for suitability for programs in oncology, infectious diseases and gene delivery.
Where Hope and Science Intersect
Providence Therapeutics’ mission is to heal the world through mRNA therapies by advancing innovative science with a patient-centred approach. Guided by its vision to be a place “Where Hope & Science Intersect,” the company is committed to developing transformative therapies while fostering optimism, compassion, and trust for patients and communities around the world.
Major Initiatives
In February 2026, Providence Therapeutics announced a world-first clinical trial to evaluate personalized mRNA cancer vaccines for children with advanced and treatment-resistant brain tumours.
The PaedNEO-VAX trial, funded by Providence Therapeutics, in combination with the Australian Government and a host of philanthropic donors, is the first multi-site pediatric study to test individualized mRNA vaccines designed specifically for each child’s cancer.
The trial is co-led by The University of Queensland and the South Australian Health and Medical Research Institute (SAHMRI) and will begin in the coming months across eight pediatric hospitals in Queensland, South Australia, New South Wales, Victoria, and Western Australia. It is sponsored by the Australia & New Zealand Children’s Haematology and Oncology Group (ANZCHOG).
Providence Therapeutics is contributing its proprietary mRNA vaccine platform and manufacturing expertise to support the creation of personalized vaccines tailored to each patient’s tumour biology. For more information, please visit providencetherapeutics.com
